The Dengue vaccine was pushed here, until they found it made some cases worse.
you see, if you get dengue once, you get sick, but if you get it again (a different strain) you can get the full hemorrhagic disease.
Wikipedia:
In 2016 a partially effective vaccine for dengue fever (Dengvaxia) became commercially available in 11 countries: Mexico, the Philippines, Indonesia, Brazil, El Salvador, Costa Rica, Paraguay, Guatemala, Peru, Thailand, and Singapore.[5][6][7] In Indonesia it costs about US$207 for the recommended three doses.[7] WHO updated its recommendations regarding the use of Dengvaxia in September 2018 based on the evidence that seronegative vaccine recipients have an excess risk of severe dengue compared to unvaccinated seronegative individuals . It is not clear why the vaccinated sereonegative population have more serious adverse outcomes. A plausible hypothesis is the phenomenon of antibody-dependent enhancement.[8]
despite the price, it was given out here en masse before the problem was discovered (and many suspect bribery was behind the push).
The 2017 dengue vaccine controversy in the Philippines involved a vaccination program run by the Philippines Department of Health.[6] It vaccinated schoolchildren with Sanofi Pasteur's CYD-TDV (Dengvaxia) dengue vaccine. Some of the children who received the vaccine had never been infected by the dengue virus before. The program was stopped when Sanofi Pasteur advised the government that the vaccine could put previously uninfected people at a somewhat higher risk of a severe case of dengue fever.[2] A political controversy erupted over whether the program was run with sufficient care and who should be held responsible for the alleged harm to the vaccinated children.[11]
but now there is a new vaccine: I found this Reuters article in a Japanese new site:
they are bypassing the USA... hmm wonder why. But here is the article and I hope Reuters doesn't sue me, because I'm too tired to paraphrase it:
CHICAGO--A new vaccine for the dengue virus is taking a potentially risky road to prevent the mosquito-borne disease that infects nearly 400 million people each year.
Takeda Pharmaceutical Co., Ltd., plans to seek approval for the experimental vaccine first in countries where the virus is endemic, rather than starting with the United States or Europe, whose rigorous reviews are often used as a benchmark worldwide, company executives told Reuters.
(italics mine)
The strategy mirrors one used by Sanofi SA, which licensed the world's first dengue vaccine, Dengvaxia, in endemic markets in 2015 before attempting to get approval from Western regulators, and forecast up to $1 billion (109 billion yen) in annual sales.
But the drugmaker failed to hit that target.
In late 2017, Sanofi disclosed that Dengvaxia could increase the risk of severe dengue in children who had never been exposed to the virus, triggering a government investigation in the Philippines where 800,000 school-age children had already been vaccinated.
Fallout from Sanofi's vaccine has raised the bar for demonstrating the safety of future dengue vaccines.
Takeda officials are banking on a different result, hopeful that their approach will help avoid the setbacks that Sanofi experienced.
On Tuesday, Takeda said its vaccine was effective at preventing all four types of dengue, meeting the main goal of its late-stage clinical trial. The company said no significant safety concerns have emerged, raising hopes it may be the next viable vaccine for the tropical virus that kills up to 25,000 people each year.
Takeda will first seek approval in each of the eight countries where its clinical trial took place: Brazil, Colombia, Panama, Dominican Republic, Nicaragua, Philippines, Thailand and Sri Lanka.
I usually am in favor of vaccines and often fight the naive SJW who hate vaccines of all sorts and hate big Pharma, mainly because I have seen these diseases and they haven't.
But here, it does make one wonder....
No comments:
Post a Comment